文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

结核分枝杆菌耐药性的演变:耐药分子决定因素综述及对个体化治疗的启示

Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

耐药结核病仍是全球结核病治疗和控制规划的重大挑战。测序技术进步增进了对抗结核药物耐药机制的理解,本综述更新了对新药、现有药物及再利用药物耐药机制的认识。全基因组测序技术有望用于结核病的快速诊断和临床管理,直接测序临床标本可在数天内诊断和检测耐药,新数据库如Relational Sequencing TB Data Platform有助于开发更好的分子诊断以实现个体化治疗并促进新药研发。

要点

  • 测序技术进步显著增进了对抗结核药物耐药机制的理解。
  • 全基因组测序标准方法因需培养菌株而缓慢,直接测序临床标本有望在数天内诊断和检测耐药。
  • Relational Sequencing TB Data Platform等新数据库收录关键耐药突变与临床结局,有助于个体化治疗和新药研发。

核心结论

  • 测序技术进展有助于开发更好的分子诊断以实现更有效的耐药结核病管理和个体化治疗,并促进改善患者结局的新药研发。

研究设计与样本

  • 综述,回顾测序技术进展对抗结核药物耐药机制理解、全基因组测序临床应用及新数据库的更新。

主要发现

  • 测序技术进步显著增进了对抗结核药物耐药机制的理解,涵盖新药、现有药物及再利用药物。
  • 全基因组测序标准方法因需培养菌株而缓慢,直接测序临床标本有望在数天内诊断和检测耐药。
  • Relational Sequencing TB Data Platform等新数据库收录全基因组序列,突出关键耐药突变和临床结局。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Drug-resistant TB (DR-TB) remains a significant challenge in TB treatment and control programmes worldwide. Advances in sequencing technology have significantly increased our understanding of the mechanisms of resistance to anti-TB drugs. This review provides an update on advances in our understanding of drug resistance mechanisms to new, existing drugs and repurposed agents. Recent advances in WGS technology hold promise as a tool for rapid diagnosis and clinical management of TB. Although the standard approach to WGS of Mycobacterium tuberculosis is slow due to the requirement for organism culture, recent attempts to sequence directly from clinical specimens have improved the potential to diagnose and detect resistance within days. The introduction of new databases may be helpful, such as the Relational Sequencing TB Data Platform, which contains a collection of whole-genome sequences highlighting key drug resistance mutations and clinical outcomes. Taken together, these advances will help devise better molecular diagnostics for more effective DR-TB management enabling personalized treatment, and will facilitate the development of new drugs aimed at improving outcomes of patients with this disease.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Dookie N, Rambaran S, Padayatchi N, et al. Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care. J Antimicrob Chemother. 2018. PMID: 29360989. doi:10.1093/jac/dkx506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。